Dupilumab: Friend or Foe to Alopecia Areata?

Dupilumab is an interleukin (IL)-4 receptor alpha antagonist approved for the treatment of moderate-to-severe atopic dermatitis. Since its approval in 2017, several case reports of dupilumab both causing and treating alopecia areata in patients with atopic dermatitis have surfaced in the literature. In the cases of new-onset or reactivation of alopecia areata, no predisposing risk factors have been identified